Katrine T. Schjoldager

TL;DR: A genetic engineering approach using human cell lines to simplify O‐glycosylation (SimpleCells) that enables proteome‐wide discovery of O-glycan sites using ‘bottom‐up’ ETD‐based mass spectrometric analysis and an improved NetOGlyc4.0 model for prediction of O‐ Glycoproteins.

TL;DR: This work predicts that use of (single-cell) transcriptomics, genetic screens, genetic engineering of cellular glycosylation capacities and custom design of glycoprotein therapeutics are advancements that will ignite wider integration of gly cosylation in general cell biology.

TL;DR: Zinc-finger nuclease gene targeting is applied to truncate the O-glycan elongation pathway in human cells, generating stable 'SimpleCell' lines with homogenous O- glycosylation and should facilitate analyses of important functions of protein gly cosylation.

TL;DR: It is demonstrated, with the use of well-defined cell systems generated by precise gene editing, that the aberrant O-glycophenotype by itself induces oncogenic features with enhanced growth and invasion, and further provides support for immunotherapeutic strategies that target aberrant o-glycans.

TL;DR: Site-specific O-glycosylation modifies pro-protein processing and other proteolytic events such as ADAM processing and thus emerges as an important co-regulator of limited proteolytics processing events.